Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and SmartPharm Therapeutics, Inc. (“SmartPharm”) announced today that Sorrento has completed the acquisition of SmartPharm, a gene-encoded protein therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases with broad potential application in enhancing any antibody-centric therapeutics.
Read the full article: Sorrento Announces the Closing of Its Acquisition of SmartPharm //
Source: https://www.globenewswire.com/news-release/2020/09/02/2087762/0/en/Sorrento-Announces-the-Closing-of-Its-Acquisition-of-SmartPharm-to-Build-Next-Generation-G-MAB-Encoded-Plasmid-DNA-For-Cost-Efficient-and-In-Vivo-Production-of-Antibody-Therapeutic.html